Emerging Role and Mechanism of Mesenchymal Stem Cells-Derived Extracellular Vesicles in Rheumatic Disease

Zhangxue Wang,Chunjuan Yang,Shushan Yan,Jiamei Sun,Jin Zhang,Zhuojian Qu,Wenchang Sun,Jie Zang,Donghua Xu

DOI: https://doi.org/10.2147/jir.s488201

IF: 4.5

2024-09-30

Journal of Inflammation Research

Abstract:Zhangxue Wang, 1, 2, &ast Chunjuan Yang, 3, &ast Shushan Yan, 4, &ast Jiamei Sun, 3, &ast Jin Zhang, 1, 2 Zhuojian Qu, 5 Wenchang Sun, 3 Jie Zang, 3 Donghua Xu 1– 3 1 School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, 261000, People's Republic of China; 2 Department of Rheumatology and Immunology, Weifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, 261000, People's Republic of China; 3 Central Laboratory, Weifang People's Hospital, Shandong Second Medical University, Weifang, Shandong, 261000, People's Republic of China; 4 Department of Gastrointestinal and Anal Diseases Surgery, Affiliated Hospital of Shandong Second Medical University, Weifang, Shandong, 261000, People's Republic of China; 5 School of Basic Medicine Sciences, Shandong Second Medical University, Weifang, Shandong, 261000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Donghua Xu; Jie Zang, Email ; Mesenchymal stem cells (MSCs) are pluripotent stem cells derived from mesoderm. Through cell-to-cell contact or paracrine effects, they carry out biological tasks like immunomodulatory, anti-inflammatory, regeneration, and repair. Extracellular vesicles (EVs) are the primary mechanism for the paracrine regulation of MSCs. They deliver proteins, nucleic acids, lipids, and other active compounds to various tissues and organs, thus facilitating intercellular communication. Rheumatic diseases may be treated using MSCs and MSC-derived EVs (MSC-EVs) due to their immunomodulatory capabilities, according to mounting data. Since MSC-EVs have low immunogenicity, high stability, and similar biological effects as to MSCs themselves, they are advantageous over cell therapy for potential therapeutic applications in rheumatoid arthritis, systemic erythematosus lupus, systemic sclerosis, Sjogren's syndrome, and other rheumatoid diseases. This review integrates recent advances in the characteristics, functions, and potential molecular mechanisms of MSC-EVs in rheumatic diseases and provides a new understanding of the pathogenesis of rheumatic diseases and MSC-EV-based treatment strategies. Keywords: mesenchymal stem cells, extracellular vesicles, exosome, immunomodulation, rheumatic disease Rheumatic diseases are refractory conditions that affect multiple systems and organs and are primarily brought on by autoimmune responses. 1 Abnormal activation of immune cells due to acute or chronic infection results in abundant immune reaction, large amounts of autoantibodies, deposition of immune complexes, and inflammatory response, which thus causes damages to specific tissues and organs, leading to arthralgia, skin lesions, myalgia, dry mouth, dry eyes, hair loss, and other clinical symptoms. The most prevalent conditions are rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjogren's syndrome (SS), and osteoarthritis (OA). Currently, hormones, antirheumatic drugs, and biological agents are the principal medications to treat rheumatic disorders. 2 However, not all patients respond well to those drug therapies, and some patients still can not achieve disease remission after standardized treatments. Furthermore, long-term use of antirheumatic drugs often leads to serious side effects in several patients with rheumatic disorders. Therefore, one problem that needs to be resolved is identifying novel therapeutic targets for rheumatic disease. Stem cells have proven beneficial in recent times for autoimmune illnesses like SLE, RA, and SSc. 3–5 MSCs widely exist in the bone marrow, umbilical cords, peripheral blood, fatty tissue, and other tissues. They are adult stem cells with multidirectional differentiation potentials. MSCs serve as a promising stem cell-based therapeutic choice and possess properties of regeneration, repair, anti-inflammation, and immunomodulation. However, MSC treatment, as a live cell therapy, inevitably has safety concerns of tumorigenicity and transplant rejection. Accumulated evidence has revealed that MSC-derived extracellular vesicles (MSC-EVs) also perform strong biological functions similar to MSCs by transferring active molecules to the corresponding organs and tissues, such as proteins, nucleic acids, and lipids. More importantly, MSC-EVs exert biological effects with excellent biocompatibility and stability in rheumatic disorders, such as exosomes, which are the most common particles with diameters less than 200 nm in size. In our previously published review, the role of MSCs and MSC-EVs in SLE has been summarized. 6 In the -Abstract Truncated-

immunology